Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.09.2012 | short review

New drugs for head and neck cancer

verfasst von: József Dudás, PhD, Heinz Zwierzina, MD, Dr. Georg Mathias Sprinzl, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Worldwide, head and neck squamous cell carcinoma (HNSCC) is the sixth most common neoplasm, and despite advances in therapy, long-term survival in HNSCC patients is poor. Primary surgery followed by chemoradiation, or primary chemoradiation, are the standard treatment options for patients with locally advanced HNSCC. Improvement in the therapy efficiency is being achieved by new derivatives of fluoropyrimidine, novel platinum compounds and targeted antibodies against the epidermal growth factor receptor. Novel targets are being developed involving integrins, cyclooxygenase, and intracellular signaling pathways. Therapeutic results are also reported for immunomodulatory drugs. Patient group stratification based on therapy relevant biomarkers might lead to improved efficiency for antibodies targeted against receptors or for kinase inhibitors.
Vorheriger Artikel The End-of-Life in patients with glioma and their families
Nächster Artikel Follow-up care for head and neck cancer patients
Literatur
1.
Cripps C, Winquist E, Devries MC, Stys-Norman D, Gilbert R. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer. Curr Oncol. 2010;17:37–48.PubMedCrossRef
2.
Tahara M, Minami H, Kawashima M, et al. Phase I trial of chemoradiotherapy with the combination of S-1 plus cisplatin for patients with unresectable locally advanced squamous cell carcinoma of the head and neck. Cancer Sci. 2011;102:419–24.PubMedCrossRef
3.
Fujii M, Tomita K, Nishijima W, et al. Phase I/II study of s-1 plus cisplatin combination chemotherapy in patients with advanced/recurrent head and neck cancer. Jpn J Clin Oncol. 2010;40:214–21.PubMedCrossRef
4.
Shiga K, Ogawa T, Kato K, Nakanome A, Kobayashi T. Adjuvant chemotherapy with S-1 for patients with head and neck cancer after radical therapy: a phase I/II feasibility study. J Clin Oncol. 2011;28:e16004 (ASCO Meeting Abstract).
5.
Sasaki Y, Tamura T, Eguchi K, et al. Pharmacokinetics of (glycolate-0,0′)-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin. Cancer Chemother Pharmacol. 1989;23:243–6.PubMedCrossRef
6.
Kurita H, Yamamoto E, Nozaki S, Wada S, Furuta I, Kurashina K. Multicenter phase I trial of induction chemotherapy with docetaxel and nedaplatin for oral squamous cell carcinoma. Oral Oncol. 2004;40:1000–6.PubMedCrossRef
7.
Ohashi T, Ohnishi M, Tanahashi S, Murai M. Efficacy and toxicity of concurrent chemoradiotherapy with nedaplatin and S-1 for head and neck cancer. Jpn J Clin Oncol. 2011;41:348–52.PubMedCrossRef
8.
Machiels JP, Schmitz S. New advances in targeted therapies for squamous cell carcinoma of the head and neck. Anticancer Drugs. 2011;22:626–33.PubMedCrossRef
9.
Frampton JE. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck. Drugs. 2010;70:1987–2010.PubMedCrossRef
10.
Vincenzi B, Zoccoli A, Pantano F, Venditti O, Galluzzo S. Cetuximab: from bench to bedside. Curr Cancer Drug Targets. 2010;10:80–95.PubMedCrossRef
11.
Sharafinski ME, Ferris RL, Ferrone S, Grandis JR. Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head Neck. 2010;32:1412–21.PubMedCrossRef
12.
Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11:21–8.PubMedCrossRef
13.
Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–78.PubMedCrossRef
14.
Ang KK, Zhang QE, Rosenthal DI, et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). J Clin Oncol. 2011;29:e5500 (ASCO Abstract).
15.
Chew A, Hay J, Laskin JJ, Wu J. Toxicity in combined modality treatment of HNSCC: cisplatin versus cetuximab. J Clin Oncol. 2011;29:e5526 (ASCO Meeting Abstract).
16.
Cohen EE, Halpern AB, Kasza K, Kocherginsky M, Williams R, Vokes EE. Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2009;45:e155–e160.PubMedCrossRef
17.
Del Campo JM, Hitt R, Sebastian P, et al. Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck. Br J Cancer. 2011;105:618–27.PubMedCrossRef
18.
Siu LL, Soulieres D, Chen EX, et al. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol. 2007;25:2178–83.PubMedCrossRef
19.
Oliveira S, Schiffelers RM, van der Veeken J, et al. Downregulation of EGFR by a novel multivalent nanobody-liposome platform. J Control Release. 2010;145:165–75.PubMedCrossRef
20.
Reardon DA, Neyns B, Weller M, Tonn JC, Nabors LB, Stupp R. Cilengitide: an RGD pentapeptide alphanubeta3 and alphanubeta5 integrin inhibitor in development for glioblastoma and other malignancies. Future Oncol. 2011;7:339–54.PubMedCrossRef
21.
Raguse JD, Gath HJ, Bier J, Riess H, Oettle H. Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour. Oral Oncol. 2004;40:228–30.PubMedCrossRef
22.
Vermorken JB, Guigay J, Mesia R, et al. Phase I/II trial of cilengitide with cetuximab, cisplatin, and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part. Br J Cancer. 2011;104:1691–6.PubMedCrossRef
23.
Lang S, Tiwari S, Andratschke M, et al. Immune restoration in head and neck cancer patients after in vivo COX-2 inhibition. Cancer Immunol Immunother. 2007;56:1645–52.PubMedCrossRef
24.
Lang S, Zeidler R. Immune restoration in head and neck cancer patients via cyclooxygenase inhibition: an update. Int J Immunopathol Pharmacol. 2003;16:41–8.PubMed
25.
Gillespie MB, Moody MW, Lee FS, et al. Head and neck cancer recurrence and mortality in nonselective cyclooxygenase inhibitor users. Arch Otolaryngol Head Neck Surg. 2007;133:28–31.PubMedCrossRef
26.
Park SW, Kim HS, Hah JW, Jeong WJ, Kim KH, Sung MW. Celecoxib inhibits cell proliferation through the activation of ERK and p38 MAPK in head and neck squamous cell carcinoma cell lines. Anticancer Drugs. 2010;21:823–30.PubMedCrossRef
27.
Wirth LJ, Haddad RI, Lindeman NI, et al. Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2005;23:6976–81.PubMedCrossRef
28.
Lai V, George J, Richey L, et al. Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract. Head Neck. 2008;30:67–74.PubMedCrossRef
29.
Feinmesser R, Hardy B, Sadov R, Shwartz A, Chretien P, Feinmesser M. Report of a clinical trial in 12 patients with head and neck cancer treated intratumorally and peritumorally with multikine. Arch Otolaryngol Head Neck Surg. 2003;129:874–81.PubMedCrossRef
30.
Barrera JL, Verastegui E, Meneses A, Zinser J, de la Garza J, Hadden JW. Combination immunotherapy of squamous cell carcinoma of the head and neck: a phase 2 trial. Arch Otolaryngol Head Neck Surg. 2000;126:345–51.PubMed
31.
Freeman SM, Franco JL, Kenady DE, et al. A phase 1 safety study of an IRX-2 regimen in patients with squamous cell carcinoma of the head and neck. Am J Clin Oncol. 2011;34:173–8.PubMed
32.
Agrawal S, Kandimalla ER. Synthetic agonists of Toll-like receptors 7, 8 and 9. Biochem Soc Trans. 2007;35:1461–7.PubMedCrossRef
33.
Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116–27.PubMedCrossRef
34.
Jun HJ, Ahn MJ, Kim HS, et al. ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer. 2008;99:167–72.PubMedCrossRef
35.
Jagdis A, Phan T, Klimowicz AC, et al. ERCC1 and XPF protein expression in patients with nasopharyngeal carcinoma (NPC) undergoing curative intent radiation with or without platinum chemotherapy. J Clin Oncol. 2011;29:e5587 (ASCO 2011 Ann Meeting Abstract).
36.
Fountzilas G, Kalogera-Fountzila A, Lambaki S, et al. MMP9 but not EGFR, MET, ERCC1, P16, and P-53 is associated with response to concomitant radiotherapy, cetuximab, and weekly cisplatin in patients with locally advanced head and neck cancer. J Oncol. 2009;2009 (305908).
37.
Fuwa N, Kodaira T, Tachibana H, Nakamura T, Daimon T. Dose escalation study of nedaplatin with 5-fluorouracil in combination with alternating radiotherapy in patients with head and neck cancer. Jpn J Clin Oncol. 2007;37:161–7.PubMedCrossRef
Metadaten
Titel
New drugs for head and neck cancer
verfasst von
József Dudás, PhD
Heinz Zwierzina, MD
Dr. Georg Mathias Sprinzl, MD
Publikationsdatum
01.09.2012
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2012
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-012-0016-1

Weitere Artikel der Ausgabe 3/2012

ASH update 2011: chronic lymphocytic leukemia and indolent lymphoma

  • short review

Follow-up care for head and neck cancer patients

  • short review

Sorafenib in thyroid cancer—a retrospective case series

  • case report

The End-of-Life in patients with glioma and their families

  • short review

Paraneoplastic neurologic disorders: a brief overview

  • short review

Brief update on recent developments in CML

  • short review